AbbVie is buying Botox maker Allergan for $63 billion – a 45% premium. It’s a great deal for the seller’s shareholders, but not much more than an overpriced superficial filler for the buyer, rob_cyran explains.
Press CTRL+C , CMD+C , or long-press the URL below on your mobile device to copy the code.
Press CTRL+C , CMD+C , or long-press the URL below on your mobile device to copy the code
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
https://www.instyle.comInStyle is the leading site for celebrity style. See expert fashion advice, star hairstyles, beauty tips, how-to videos and real-time red carpet coverage.
Read more »
Allergan spikes 30% after AbbVie agrees to buy the Botox-maker for $63 billionAbbVie expects the acquisition to generate at least $2 billion in pre-tax synergies and cost reductions within three years.
Read more »
AbbVie looks beyond Humira with $63 billion deal for Botox-maker AllerganDrugmaker AbbVie Inc said on Tuesday it would buy Botox-maker Allergan Plc for a...
Read more »
Aging AbbVie turns to ugly $63 bln Botox remedyThe drug maker’s Humira accounts for more than half its sales but may soon face competition. Buying Botox maker Allergan at a 45% premium looks like an excessively expensive and temporary face-lift. AbbVie’s money and time could be better spent on more invigorating targets.
Read more »
AbbVie to acquire Botox maker Allergan with $63-billion bidAbbVie said it will pay $120.30 in cash and a portion of AbbVie stock for each Allergan share.
Read more »